{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:48:53Z","timestamp":1793216933176,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Startup Fund for Scientific Research of Fujian Medical University","award":["2020QH1239"],"award-info":[{"award-number":["2020QH1239"]}]},{"DOI":"10.13039\/501100003392","name":"\u798f\u5efa\u7701\u79d1\u6280\u5385 Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J011482"],"award-info":[{"award-number":["2023J011482"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"\u798f\u5efa\u7701\u79d1\u6280\u5385 Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2021J011294"],"award-info":[{"award-number":["2021J011294"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis","award":["CSED-ZDSYS-202302"],"award-info":[{"award-number":["CSED-ZDSYS-202302"]}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62175031"],"award-info":[{"award-number":["62175031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2025,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoantigen vaccine is a promising breakthrough in tumor immunotherapy. However, the application of this highly personalized strategy in the treatment of solid tumors is hindered by several obstacles, including very costly and time-consuming preparation steps, uncertainty in prediction algorithms and tumor heterogeneity. Universalization of neoantigen vaccine is an ideal yet currently unattainable solution to such limitations. To overcome these limitations, we engineered oncolytic viruses co-expressing neoantigens and neoantigen-binding major histocompatibility complex (MHC) molecules to force ectopic delivery of peptide-MHC ligands to T cell receptors (TCRs), enabling specific targeting by neoantigen vaccine-primed host immunity. When integrated with neoantigen vaccination, the engineered viruses exhibited potent cytolytic activity in a variety of tumor models irrespective of the neoantigen expression profiles, eliciting robust systemic antitumor immunity to reject tumor rechallenge and inhibit abscopal tumor growth with a favorable safety profile. Thus, this study provides a powerful approach to enhance the universality and efficacy of neoantigen vaccines, meeting the urgent need for universal neoantigen vaccines in the clinic to facilitate the further development of tumor immunotherapy.<\/jats:p>","DOI":"10.1038\/s44321-025-00225-3","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:55:06Z","timestamp":1744005306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0451-5346","authenticated-orcid":false,"given":"Chenyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7324-3121","authenticated-orcid":false,"given":"Yingjun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3538-7917","authenticated-orcid":false,"given":"Junjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4981","authenticated-orcid":false,"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"225_CR1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coi.2021.04.009","volume":"70","author":"ET Abualrous","year":"2021","unstructured":"Abualrous ET, Sticht J, Freund C (2021) Major histocompatibility complex (MHC) class I and class II proteins: impact of polymorphism on antigen presentation. Curr Opin Immunol 70:95\u2013104","journal-title":"Curr Opin Immunol"},{"key":"225_CR2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jmb.2005.11.068","volume":"356","author":"A Achour","year":"2006","unstructured":"Achour A, Michaelsson J, Harris RA, Ljunggren HG, Karre K, Schneider G, Sandalova T (2006) Structural basis of the differential stability and receptor specificity of H-2Db in complex with murine versus human beta2-microglobulin. J Mol Biol 356:382\u2013396","journal-title":"J Mol Biol"},{"key":"225_CR3","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/s41596-019-0170-6","volume":"14","author":"M Ali","year":"2019","unstructured":"Ali M, Foldvari Z, Giannakopoulou E, Boschen ML, Stronen E, Yang W, Toebes M, Schubert B, Kohlbacher O, Schumacher TN et al (2019) Induction of neoantigen-reactive T cells from healthy donors. Nat Protoc 14:1926\u20131943","journal-title":"Nat Protoc"},{"key":"225_CR4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17513758.2018.1498984","volume":"13","author":"F Bai","year":"2019","unstructured":"Bai F, Huff KES, Allen LJS (2019) The effect of delay in viral production in within-host models during early infection. J Biol Dyn 13:47\u201373","journal-title":"J Biol Dyn"},{"key":"225_CR5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","volume":"14","author":"GE Blair","year":"1989","unstructured":"Blair GE, Dixon SC, Griffiths SA, Zajdel ME (1989) Restricted replication of human adenovirus type 5 in mouse cell lines. Virus Res 14:339\u2013346","journal-title":"Virus Res"},{"key":"225_CR6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA (2021) Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 18:215\u2013229","journal-title":"Nat Rev Clin Oncol"},{"key":"225_CR7","doi-asserted-by":"crossref","first-page":"e954893","DOI":"10.4161\/21624011.2014.954893","volume":"3","author":"S Boegel","year":"2014","unstructured":"Boegel S, Lower M, Bukur T, Sahin U, Castle JC (2014) A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology 3:e954893","journal-title":"Oncoimmunology"},{"key":"225_CR8","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS et al (2020) mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest 130:5976\u20135988","journal-title":"J Clin Invest"},{"key":"225_CR9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER et al (2015) Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348:803\u2013808","journal-title":"Science"},{"key":"225_CR10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/eji.201243088","volume":"43","author":"CX Chang","year":"2013","unstructured":"Chang CX, Tan AT, Or MY, Toh KY, Lim PY, Chia AS, Froesig TM, Nadua KD, Oh HL, Leong HN et al (2013) Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases. Eur J Immunol 43:1109\u20131120","journal-title":"Eur J Immunol"},{"key":"225_CR11","doi-asserted-by":"crossref","first-page":"e004389","DOI":"10.1136\/jitc-2021-004389","volume":"10","author":"H Chen","year":"2022","unstructured":"Chen H, Li Z, Qiu L, Dong X, Chen G, Shi Y, Cai L, Liu W, Ye H, Zhou Y et al (2022) Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. J Immunother Cancer 10:e004389","journal-title":"J Immunother Cancer"},{"key":"225_CR12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","volume":"121","author":"N Cieri","year":"2013","unstructured":"Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F et al (2013) IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121:573\u2013584","journal-title":"Blood"},{"key":"225_CR13","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/s41388-018-0187-2","volume":"37","author":"DL Crossland","year":"2018","unstructured":"Crossland DL, Denning WL, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Gold KS, Glisson BS et al (2018) Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene 37:3686\u20133697","journal-title":"Oncogene"},{"key":"225_CR14","doi-asserted-by":"crossref","first-page":"e2116738119","DOI":"10.1073\/pnas.2116738119","volume":"119","author":"N Cuburu","year":"2022","unstructured":"Cuburu N, Bialkowski L, Pontejo SM, Sethi SK, Bell ATF, Kim R, Thompson CD, Lowy DR, Schiller JT (2022) Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. Proc Natl Acad Sci USA 119:e2116738119","journal-title":"Proc Natl Acad Sci USA"},{"key":"225_CR15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo7604","volume":"14","author":"AM D\u2019Alise","year":"2022","unstructured":"D\u2019Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S et al (2022) Adenoviral-based vaccine promotes neoantigen-specific CD8(+) T cell stemness and tumor rejection. Sci Transl Med 14:eabo7604","journal-title":"Sci Transl Med"},{"key":"225_CR16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10594-2","volume":"10","author":"AM D\u2019Alise","year":"2019","unstructured":"D\u2019Alise AM, Leoni G, Cotugno G, Troise F, Langone F, Fichera I, De Lucia M, Avalle L, Vitale R, Leuzzi A et al (2019) Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nat Commun 10:2688","journal-title":"Nat Commun"},{"key":"225_CR17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/cgt.2014.32","volume":"21","author":"AB Del Campo","year":"2014","unstructured":"Del Campo AB, Carretero J, Munoz JA, Zinchenko S, Ruiz-Cabello F, Gonzalez-Aseguinolaza G, Garrido F, Aptsiauri N (2014) Adenovirus expressing beta2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition. Cancer Gene Ther 21:317\u2013332","journal-title":"Cancer Gene Ther"},{"key":"225_CR18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/320232a0","volume":"320","author":"Z Dembic","year":"1986","unstructured":"Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H, Steinmetz M (1986) Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320:232\u2013238","journal-title":"Nature"},{"key":"225_CR19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL (2021) Cancer immune evasion through loss of MHC Class I antigen presentation. Front Immunol 12:636568","journal-title":"Front Immunol"},{"key":"225_CR20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2326-6066.CIR-18-0283","volume":"7","author":"EK Duperret","year":"2019","unstructured":"Duperret EK, Perales-Puchalt A, Stoltz RGHH, Mandloi N, Barlow J, Chaudhuri A, Sardesai NY, Weiner DB (2019) A synthetic DNA, multi-neoantigen vaccine drives predominately MHC Class I CD8(+) T-cell responses, impacting tumor challenge. Cancer Immunol Res 7:174\u2013182","journal-title":"Cancer Immunol Res"},{"key":"225_CR21","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4049\/jimmunol.170.3.1416","volume":"170","author":"JC Fitzgerald","year":"2003","unstructured":"Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, Giles-Davis W, Wilson JM, Ertl HC (2003) A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170:1416\u20131422","journal-title":"J Immunol"},{"key":"225_CR22","doi-asserted-by":"crossref","first-page":"e001046","DOI":"10.1136\/jitc-2020-001046","volume":"8","author":"JC Flickinger Jr","year":"2020","unstructured":"Flickinger JC, Jr Singh J, Carlson R, Leong E, Baybutt TR, Barton J, Caparosa E, Pattison A, Rappaport JA, Roh J et al (2020) Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. J Immunother Cancer 8:e001046","journal-title":"J Immunother Cancer"},{"key":"225_CR23","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/JVI.74.6.2895-2899.2000","volume":"74","author":"I Ganly","year":"2000","unstructured":"Ganly I, Mautner V, Balmain A (2000) Productive replication of human adenoviruses in mouse epidermal cells. J Virol 74:2895\u20132899","journal-title":"J Virol"},{"key":"225_CR24","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, Meyer C, Stewig B, Xie Y, Bu X et al (2021) Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov 11:1524\u20131541","journal-title":"Cancer Discov"},{"key":"225_CR25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00285-021-01612-3","volume":"82","author":"H Gulbudak","year":"2021","unstructured":"Gulbudak H, Salceanu PL, Wolkowicz GSK (2021) A delay model for persistent viral infections in replicating cells. J Math Biol 82:59","journal-title":"J Math Biol"},{"key":"225_CR26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC (2019) Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 18:689\u2013706","journal-title":"Nat Rev Drug Discov"},{"key":"225_CR27","doi-asserted-by":"crossref","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","volume":"371","author":"EH Hsiue","year":"2021","unstructured":"Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q et al (2021) Targeting a neoantigen derived from a common TP53 mutation. Science 371:eabc8697","journal-title":"Science"},{"key":"225_CR28","volume":"10","author":"H Huang","year":"2019","unstructured":"Huang H, Liu Y, Liao W, Cao Y, Liu Q, Guo Y, Lu Y, Xie Z (2019) Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nat Commun 10:4801","journal-title":"Nat Commun"},{"key":"225_CR29","volume":"21","author":"L Huang","year":"2022","unstructured":"Huang L, Rong Y, Tang X, Yi K, Qi P, Hou J, Liu W, He Y, Gao X, Yuan C et al (2022) Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer 21:45","journal-title":"Mol Cancer"},{"key":"225_CR30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/1878-0261.12628","volume":"14","author":"Y Huang","year":"2020","unstructured":"Huang Y, Lv SQ, Liu PY, Ye ZL, Yang H, Li LF, Zhu HL, Wang Y, Cui LZ, Jiang DQ et al (2020) A SIRPalpha-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol Oncol 14:657\u2013668","journal-title":"Mol Oncol"},{"key":"225_CR31","doi-asserted-by":"crossref","first-page":"e004762","DOI":"10.1136\/jitc-2022-004762","volume":"10","author":"F Ju","year":"2022","unstructured":"Ju F, Luo Y, Lin C, Jia X, Xu Z, Tian R, Lin Y, Zhao M, Chang Y, Huang X et al (2022) Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. J Immunother Cancer 10:e004762","journal-title":"J Immunother Cancer"},{"key":"225_CR32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biomaterials.2017.09.009","volume":"147","author":"BK Jung","year":"2017","unstructured":"Jung BK, Oh E, Hong J, Lee Y, Park KD, Yun CO (2017) A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response. Biomaterials 147:26\u201338","journal-title":"Biomaterials"},{"key":"225_CR33","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","volume":"28","author":"N Kanaya","year":"2020","unstructured":"Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M, Morihiro T, Kubota T, Aoyama K, Kikuchi S et al (2020) Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody. Mol Ther 28:794\u2013804","journal-title":"Mol Ther"},{"key":"225_CR34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","volume":"10","author":"T Kawashima","year":"2004","unstructured":"Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10:285\u2013292","journal-title":"Clin Cancer Res"},{"key":"225_CR35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41417-018-0063-9","volume":"26","author":"V Kemp","year":"2019","unstructured":"Kemp V, van den Wollenberg DJM, Camps MGM, van Hall T, Kinderman P, Pronk-van Montfoort N, Hoeben RC (2019) Arming oncolytic reovirus with GM-CSF gene to enhance immunity. Cancer Gene Ther 26:268\u2013281","journal-title":"Cancer Gene Ther"},{"key":"225_CR36","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838\u20131847","journal-title":"N Engl J Med"},{"key":"225_CR37","doi-asserted-by":"crossref","first-page":"e001292","DOI":"10.1136\/jitc-2020-001292","volume":"9","author":"H Khalique","year":"2021","unstructured":"Khalique H, Baugh R, Dyer A, Scott EM, Frost S, Larkin S, Lei-Rossmann J, Seymour LW (2021) Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. J Immunother Cancer 9:e001292","journal-title":"J Immunother Cancer"},{"key":"225_CR38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.mt.6300321","volume":"16","author":"F Kreppel","year":"2008","unstructured":"Kreppel F, Kochanek S (2008) Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 16:16\u201329","journal-title":"Mol Ther"},{"key":"225_CR39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang F, Schrors B, Lower M, Tureci O, Sahin U (2022) Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov 21:261\u2013282","journal-title":"Nat Rev Drug Discov"},{"key":"225_CR40","doi-asserted-by":"crossref","first-page":"e000131","DOI":"10.1136\/jitc-2019-000131","volume":"8","author":"F Li","year":"2020","unstructured":"Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S, Zhang Y (2020) CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer 8:e000131","journal-title":"J Immunother Cancer"},{"key":"225_CR41","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/mt.2010.312","volume":"19","author":"J Li","year":"2011","unstructured":"Li J, O\u2019Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL (2011) Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 19:650\u2013657","journal-title":"Mol Ther"},{"key":"225_CR42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402\u2013408","journal-title":"Methods"},{"key":"225_CR43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","volume":"606","author":"M \u0141uksza","year":"2022","unstructured":"\u0141uksza M, Sethna ZM, Rojas LA, Lihm J, Bravi B, Elhanati Y, Soares K, Amisaki M, Dobrin A, Hoyos D et al (2022) Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606:389\u2013395","journal-title":"Nature"},{"key":"225_CR44","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","volume":"120","author":"RJ Malonis","year":"2020","unstructured":"Malonis RJ, Lai JR, Vergnolle O (2020) Peptide-based vaccines: current progress and future challenges. Chem Rev 120:3210\u20133229","journal-title":"Chem Rev"},{"key":"225_CR45","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","volume":"26","author":"NT Martin","year":"2018","unstructured":"Martin NT, Bell JC (2018) Oncolytic virus combination therapy: killing one bird with two stones. Mol Ther 26:1414\u20131422","journal-title":"Mol Ther"},{"key":"225_CR46","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1099\/vir.0.79940-0","volume":"85","author":"T Matsushita","year":"2004","unstructured":"Matsushita T, Okada T, Inaba T, Mizukami H, Ozawa K, Colosi P (2004) The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus vector production. J Gen Virol 85:2209\u20132214","journal-title":"J Gen Virol"},{"key":"225_CR47","doi-asserted-by":"crossref","unstructured":"McGranahan N, Swanton C (2019) Neoantigen quality, not quantity. Sci Trans Med 11, eaax7918:1\u20133","DOI":"10.1126\/scitranslmed.aax7918"},{"key":"225_CR48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41587-019-0404-8","volume":"38","author":"DG Millar","year":"2020","unstructured":"Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K et al (2020) Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol 38:420\u2013425","journal-title":"Nat Biotechnol"},{"key":"225_CR49","first-page":"PO.20.00395","volume":"5","author":"O Moaven","year":"2021","unstructured":"Moaven O, WM C, AS J, Anastasiadis PZ, Borad MJ (2021) Evolving role of oncolytic virotherapy: challenges and prospects in clinical practice. JCO Precis Oncol 5:PO.20.00395","journal-title":"JCO Precis Oncol"},{"key":"225_CR50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg5841","volume":"7","author":"EA Ogunnaike","year":"2021","unstructured":"Ogunnaike EA, Valdivia A, Yazdimamaghani M, Leon E, Nandi S, Hudson H, Du H, Khagi S, Gu Z, Savoldo B et al (2021) Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma. Sci Adv 7:eabg5841","journal-title":"Sci Adv"},{"key":"225_CR51","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","volume":"12","author":"AK Park","year":"2020","unstructured":"Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, Jeang B, Chang WC, Chen NG, Thomas SH et al (2020) Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med 12:eaaz1863","journal-title":"Sci Transl Med"},{"key":"225_CR52","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-18-2311","volume":"25","author":"C Passaro","year":"2019","unstructured":"Passaro C, Alayo Q, De Laura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K et al (2019) Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin Cancer Res 25:290\u2013299","journal-title":"Clin Cancer Res"},{"key":"225_CR53","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","volume":"2","author":"AH Pearlman","year":"2021","unstructured":"Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, Mog BJ, Bettegowda C, Pardoll DM, Gabelli SB et al (2021) Targeting public neoantigens for cancer immunotherapy. Nat Cancer 2:487\u2013497","journal-title":"Nat Cancer"},{"key":"225_CR54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, Gundem G, Domenico D, Mitra S, Socci ND et al (2025) CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med 392:577\u2013583","journal-title":"N Engl J Med"},{"key":"225_CR55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-pathol-020117-043720","volume":"13","author":"E Perkey","year":"2018","unstructured":"Perkey E, Maillard I (2018) New insights into graft-versus-host disease and graft rejection. Annu Rev Pathol 13:219\u2013245","journal-title":"Annu Rev Pathol"},{"key":"225_CR56","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.3390\/cancers12061563","volume":"12","author":"M Pulido","year":"2020","unstructured":"Pulido M, Chamorro V, Romero I, Algarra I, S-Montalvo A, Collado A, Garrido F, Garcia-Lora AM (2020) Restoration of MHC-I on tumor cells by fhit transfection promotes immune rejection and acts as an individualized immunotherapeutic vaccine. Cancers (Basel) 12:eaaz1863","journal-title":"Cancers (Basel)"},{"key":"225_CR57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17:147\u2013167","journal-title":"Nat Rev Clin Oncol"},{"key":"225_CR58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, Gogenur I (2021) Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer 124:359\u2013367","journal-title":"Br J Cancer"},{"key":"225_CR59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41586-024-08033-4","volume":"635","author":"A Redenti","year":"2024","unstructured":"Redenti A, Im J, Redenti B, Li F, Rouanne M, Sheng Z, Sun W, Gurbatri CR, Huang S, Komaranchath M et al (2024) Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature 635:453\u2013461","journal-title":"Nature"},{"key":"225_CR60","doi-asserted-by":"crossref","first-page":"e003978","DOI":"10.1136\/jitc-2021-003978","volume":"10","author":"D Reparaz","year":"2022","unstructured":"Reparaz D, Ruiz M, Llopiz D, Silva L, Vercher E, Aparicio B, Egea J, Tamayo-Uria I, Hervas-Stubbs S, Garcia-Balduz J et al (2022) Neoantigens as potential vaccines in hepatocellular carcinoma. J Immunother Cancer 10:e003978","journal-title":"J Immunother Cancer"},{"key":"225_CR61","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/nprot.2011.379","volume":"6","author":"DN Rockwood","year":"2011","unstructured":"Rockwood DN, Preda RC, Yucel T, Wang X, Lovett ML, Kaplan DL (2011) Materials fabrication from Bombyx mori silk fibroin. Nat Protoc 6:1612\u20131631","journal-title":"Nat Protoc"},{"key":"225_CR62","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08534-1","volume":"10","author":"PC Rosato","year":"2019","unstructured":"Rosato PC, Wijeyesinghe S, Stolley JM, Nelson CE, Davis RL, Manlove LS, Pennell CA, Blazar BR, Chen CC, Geller MA et al (2019) Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat Commun 10:567","journal-title":"Nat Commun"},{"key":"225_CR63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, Bukur V, Tadmor AD, Luxemburger U, Schrors B et al (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547:222\u2013226","journal-title":"Nature"},{"key":"225_CR64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","volume":"4","author":"M Saxena","year":"2018","unstructured":"Saxena M, Bhardwaj N (2018) Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer 4:119\u2013137","journal-title":"Trends Cancer"},{"key":"225_CR65","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-015-0240-5","volume":"7","author":"J Scholtalbers","year":"2015","unstructured":"Scholtalbers J, Boegel S, Bukur T, Byl M, Goerges S, Sorn P, Loewer M, Sahin U, Castle JC (2015) TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med 7:118","journal-title":"Genome Med"},{"key":"225_CR66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2567.2008.03015.x","volume":"126","author":"JD Stone","year":"2009","unstructured":"Stone JD, Chervin AS, Kranz DM (2009) T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126:165\u2013176","journal-title":"Immunology"},{"key":"225_CR67","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.aaf2288","volume":"352","author":"E Stronen","year":"2016","unstructured":"Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Boschen ML, Lund-Johansen F, Olweus J et al (2016) Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352:1337\u20131341","journal-title":"Science"},{"key":"225_CR68","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/JVI.78.6.2666-2673.2004","volume":"78","author":"SM Sumida","year":"2004","unstructured":"Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S et al (2004) Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78:2666\u20132673","journal-title":"J Virol"},{"key":"225_CR69","first-page":"169","volume":"130","author":"MA Thomas","year":"2007","unstructured":"Thomas MA, Spencer JF, Wold WS (2007) Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 130:169\u2013183","journal-title":"Methods Mol Med"},{"key":"225_CR70","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41434-021-00256-8","volume":"30","author":"L Tian","year":"2023","unstructured":"Tian L, Liu T, Jiang S, Cao Y, Kang K, Su H, Ren G, Wang Z, Xiao W, Li D (2023) Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy. Gene Ther 30:64\u201374","journal-title":"Gene Ther"},{"key":"225_CR71","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20:651\u2013668","journal-title":"Nat Rev Immunol"},{"key":"225_CR72","volume":"11","author":"G Wang","year":"2020","unstructured":"Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, Chen SY (2020) An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun 11:1395","journal-title":"Nat Commun"},{"key":"225_CR73","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WS Wold","year":"2013","unstructured":"Wold WS, Toth K (2013) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13:421\u2013433","journal-title":"Curr Gene Ther"},{"key":"225_CR74","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/1878-0261.13483","volume":"17","author":"Y Wolf","year":"2023","unstructured":"Wolf Y, Sameuls Y (2023) Neoantigens in cancer immunotherapy: quantity vs. quality. Mol Oncol 17:1457\u20131459","journal-title":"Mol Oncol"},{"key":"225_CR75","volume":"11","author":"S Wu","year":"2020","unstructured":"Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, Wang B, Zhao Z, Song X, Chen Y et al (2020) A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 11:4081","journal-title":"Nat Commun"},{"key":"225_CR76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L (2023) Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther 8:9","journal-title":"Signal Transduct Target Ther"},{"key":"225_CR77","volume":"12","author":"B Xu","year":"2021","unstructured":"Xu B, Tian L, Chen J, Wang J, Ma R, Dong W, Li A, Zhang J, Antonio Chiocca E, Kaur B et al (2021) An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. Nat Commun 12:5908","journal-title":"Nat Commun"},{"key":"225_CR78","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1002\/j.1460-2075.1987.tb02563.x","volume":"6","author":"G Yamada","year":"1987","unstructured":"Yamada G, Kitamura Y, Sonoda H, Harada H, Taki S, Mulligan RC, Osawa H, Diamantstein T, Yokoyama S, Taniguchi T (1987) Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 6:2705\u20132709","journal-title":"EMBO J"},{"key":"225_CR79","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y, Qiu L, Wu Q, Sun Z, Ye X et al (2022) Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J 12:104","journal-title":"Blood Cancer J"},{"key":"225_CR80","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","volume":"108","author":"AK Zaiss","year":"2009","unstructured":"Zaiss AK, Machado HB, Herschman HR (2009) The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 108:778\u2013790","journal-title":"J Cell Biochem"},{"key":"225_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acssynbio.1c00256","volume":"11","author":"C Zhang","year":"2022","unstructured":"Zhang C, Zhuang Q, Liu J, Liu X (2022) Synthetic biology in chimeric antigen receptor T (CAR T) cell engineering. ACS Synth Biol 11:1\u201315","journal-title":"ACS Synth Biol"},{"key":"225_CR82","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1021\/acs.nanolett.1c04977","volume":"22","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Wang Y, Zhao B, Chen H, Cai Z, Zheng Y, Zeng Y, Zhang D, Liu X (2022) Neoantigen immunotherapeutic-gel combined with TIM-3 blockade effectively restrains orthotopic hepatocellular carcinoma progression. Nano Lett 22:2048\u20132058","journal-title":"Nano Lett"},{"key":"225_CR83","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gkac997","volume":"51","author":"X Zhao","year":"2023","unstructured":"Zhao X, Ma S, Wang B, Jiang X, Xu S (2023) PGG.MHC: toward understanding the diversity of major histocompatibility complexes in human populations. Nucleic Acids Res 51:D1102\u2013d1108","journal-title":"Nucleic Acids Res"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00225-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-025-00225-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00225-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:39Z","timestamp":1786980279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-025-00225-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,14]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1038\/s44321-025-00225-3","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"15"}}